These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Aldosterone and volume management in hypertensive heart disease. Sica DA Semin Nephrol; 2014 May; 34(3):323-32. PubMed ID: 25016402 [TBL] [Abstract][Full Text] [Related]
30. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Hu X; Li S; McMahon EG; Lala DS; Rudolph AE Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407 [TBL] [Abstract][Full Text] [Related]
31. Eplerenone. Brown R; Quirk J; Kirkpatrick P Nat Rev Drug Discov; 2003 Mar; 2(3):177-8. PubMed ID: 12619638 [No Abstract] [Full Text] [Related]
32. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension. Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561 [TBL] [Abstract][Full Text] [Related]
33. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767 [TBL] [Abstract][Full Text] [Related]
34. Does eplerenone have a future in the management of hypertension in Europe? Gosse P; Macfadyen RJ J Hum Hypertens; 2006 Nov; 20(11):829-32. PubMed ID: 16915301 [No Abstract] [Full Text] [Related]
35. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. O'Keefe JH; Abuissa H; Pitt B Diabetes Obes Metab; 2008 Jun; 10(6):492-7. PubMed ID: 17490427 [TBL] [Abstract][Full Text] [Related]
36. Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats. Nakamura T; Fukuda M; Kataoka K; Nako H; Tokutomi Y; Dong YF; Yamamoto E; Yasuda O; Ogawa H; Kim-Mitsuyama S Hypertens Res; 2011 Jul; 34(7):817-24. PubMed ID: 21471977 [TBL] [Abstract][Full Text] [Related]
37. New biology of aldosterone, and experimental studies on the selective aldosterone blocker eplerenone. Funder JW Am Heart J; 2002 Nov; 144(5 Suppl):S8-11. PubMed ID: 12422135 [No Abstract] [Full Text] [Related]
38. Adherence to aldosterone-blocking agents in patients with heart failure. Margolis J; Gerber RA; Roberts C; Gheorghiade M Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344 [TBL] [Abstract][Full Text] [Related]
39. [The revived interest in aldosterone antagonists]. Waeber B Rev Med Suisse; 2006 Sep; 2(78):2055-8. PubMed ID: 17019841 [TBL] [Abstract][Full Text] [Related]
40. Eplerenone is not superior to older and less expensive aldosterone antagonists. Chatterjee S; Moeller C; Shah N; Bolorunduro O; Lichstein E; Moskovits N; Mukherjee D Am J Med; 2012 Aug; 125(8):817-25. PubMed ID: 22840667 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]